Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sparsentan (SPAR), a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), led to sustained proteinuria reductions in patients (pts) with focal segmental glomerulosclerosis (FSGS) in DUPLEX. We investigated the comparative effects of SPAR vs irbesartan (IRB) on varying low proteinuria targets in DUPLEX. Additionally, we assessed the impact of reaching the FSGS partial remission endpoint (FPRE; defined as urine protein-to-creatinine ratio [UPCR] of ≤1.5 g/g and >40% reduction from baseline), complete remission of proteinuria (CR; defined as UPCR of <0.3 g/g), or UPCR of <0.7 g/g (a clinically meaningful low proteinuria threshold as identified by the PARASOL Initiative) on progression to kidney failure during the trial.
DUPLEX (NCT03493685) was a randomized, 108-wk, phase 3 study of SPAR (n=184; 800 mg/d) vs IRB (n=187; 300 mg/d) in pts with FSGS (without known secondary cause). Outcomes included FPRE, CR, and proteinuria reductions to UPCR of <0.5 g/g, <0.7 g/g, <1.0 g/g, or <1.5 g/g. Post hoc analyses using SPAR/IRB pooled data examined the effect of achieving FPRE, CR, or UPCR <0.7 g/g, at any time during the double-blind period on progression to kidney failure (KF [confirmed estimated glomerular filtration rate <15 mL/min/1.73 m2 or kidney replacement therapy]).
Pts achieved all low proteinuria targets earlier and more frequently with SPAR vs IRB. The percentages of pts reaching FPRE, CR, and UPCR of <0.5 g/g, <0.7 g/g, <1.0 g/g, and <1.5 g/g at any time through 108 wk with SPAR vs IRB (relative risk [95% CI]) were 64.7% vs 43.9% (1.48 [1.23-1.78]), 18.5% vs 7.5% (2.47 [1.37-4.45]), 31.0% vs 14.4% (2.15 [1.44-3.20]), 38% vs 23% (1.7 [1.2-2.3], 53.3% vs 35.8% (1.49 [1.19-1.86]), and 69.0% vs 50.8% (1.36 [1.16-1.59]), respectively. Between–treatment group differences for median time to reach all proteinuria targets favored SPAR (P≤.0008 for all endpoints). Irrespective of treatment arm, fewer pts reached KF among those who did vs those who did not achieve FPRE (3.0% vs 15.9%; relative risk [RR], 0.33 [95% CI 0.11-0.95]), CR (2.1% vs 9.9%; RR, 0.23 [95% CI 0.03-1.85]), or UPCR <0.7 g/g (3.6% vs 11.2%; RR, 0.52 [0.2-1.8]) during the trial. SPAR was generally well tolerated, with no new safety concerns.
Pts with FSGS achieved clinically meaningful low proteinuria thresholds, including FPRE, CR, and UPCR <0.7 g/g, earlier and more often with SPAR vs IRB. Pts who reached FPRE, CR, or UPCR <0.7 g/g, were less likely to reach KF vs those who did not, supporting the nephroprotective benefit of SPAR in FSGS.
This abstract was also submitted for the European Renal Association 2025 congress.
